Frank Mottola is VP at SUPERNUS PHARMACEUTICALS, INC. (SUPN). They have made 6 open-market trades across 1 company since 2023, most recently 2026-08-12.
CIK 0001804567
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SUPN | 19,544 | $740K |
Shares reported on the most recent Form 4, priced at the 2026-08-14 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SUPN | SELL | 2026-03-09 | 2026-03-10 | $53.65 | $87K | -10.2% | -3.1% | -16.3% |
| SUPN | SELL · 10b5-1 | 2025-12-19 | 2025-12-22 | $50.41 | $1.0M | -4.0% | -3.8% | -4.3% |
| SUPN | SELL | 2025-09-12 | 2025-09-15 | $45.87 | $229K | +7.3% | +12.1% | +7.6% |
| SUPN | SELL | 2025-08-25 | 2025-08-27 | $44.51 | $623K | +2.1% | +4.3% | +2.2% |
| SUPN | SELL | 2024-11-07 | 2024-11-08 | $36.98 | $555K | -2.2% | -0.7% | +5.2% |
| SUPN | SELL | 2023-11-14 | 2023-11-16 | $28.13 | $31K | -4.3% | -3.1% | -2.1% |
| SUPN | SELL | 2023-03-14 | 2023-03-16 | $35.99 | $344K | +2.3% | +3.3% | -5.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.